Immutep Limited (IMM.AX)
AUD 0.3
(11.11%)
AUD 0.3
(11.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 1.44 Million AUD | 176.27% |
| 2021 | -1.89 Million AUD | -205.6% |
| 2020 | 1.79 Million AUD | 111.96% |
| 2019 | -14.98 Million AUD | 8.91% |
| 2018 | -16.45 Million AUD | -123.54% |
| 2017 | -7.35 Million AUD | -404.72% |
| 2016 | 2.41 Million AUD | 135.08% |
| 2015 | -6.88 Million AUD | 2.74% |
| 2014 | -7.07 Million AUD | 25.52% |
| 2013 | -9.5 Million AUD | 13.12% |
| 2012 | -10.93 Million AUD | -819.66% |
| 2011 | 1.52 Million AUD | 0.0% |
| 2010 | - AUD | -100.0% |
| 2009 | 523.73 Thousand AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 Q2 | 750.33 Thousand AUD | 0.0% |
| 2022 Q4 | 896.16 Thousand AUD | 0.0% |
| 2022 FY | 1.44 Million AUD | 176.27% |
| 2021 FY | -1.89 Million AUD | -205.6% |
| 2021 Q2 | 1.13 Million AUD | 0.0% |
| 2021 Q4 | -946.33 Thousand AUD | 0.0% |
| 2020 FY | 1.79 Million AUD | 111.96% |
| 2020 Q4 | 633.02 Thousand AUD | 0.0% |
| 2020 Q2 | 1.15 Million AUD | 0.0% |
| 2019 Q2 | -4.53 Million AUD | 0.0% |
| 2019 FY | -14.98 Million AUD | 8.91% |
| 2019 Q4 | -10.45 Million AUD | 0.0% |
| 2018 Q4 | -8.86 Million AUD | 0.0% |
| 2018 Q2 | -5.3 Million AUD | 0.0% |
| 2018 FY | -16.45 Million AUD | -123.54% |
| 2017 FY | -7.35 Million AUD | -404.72% |
| 2017 Q4 | -2.72 Million AUD | 0.0% |
| 2017 Q2 | -410.09 Thousand AUD | 0.0% |
| 2016 Q3 | - AUD | 100.0% |
| 2016 Q4 | -2.28 Million AUD | 0.0% |
| 2016 FY | 2.41 Million AUD | 135.08% |
| 2016 Q2 | -1.11 Million AUD | 0.0% |
| 2015 FY | -6.88 Million AUD | 2.74% |
| 2015 Q4 | -3.04 Million AUD | 0.0% |
| 2015 Q3 | - AUD | 100.0% |
| 2015 Q2 | -2.74 Million AUD | 0.0% |
| 2014 Q2 | -3.72 Million AUD | 0.0% |
| 2014 FY | -7.07 Million AUD | 25.52% |
| 2014 Q4 | -3.89 Million AUD | 0.0% |
| 2013 Q2 | -4.37 Million AUD | 0.0% |
| 2013 FY | -9.5 Million AUD | 13.12% |
| 2013 Q4 | -5.53 Million AUD | 0.0% |
| 2012 FY | -10.93 Million AUD | -819.66% |
| 2012 Q4 | -6.56 Million AUD | 0.0% |
| 2012 Q2 | -5.79 Million AUD | 0.0% |
| 2011 FY | 1.52 Million AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | -100.0% |
| 2009 FY | 523.73 Thousand AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | 4.245% |
| Acrux Limited | -1.28 Million AUD | 212.454% |
| Actinogen Medical Limited | 9.93 Million AUD | 85.461% |
| AnteoTech Limited | 460.39 Thousand AUD | -213.622% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 44.421% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 5657.966% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 292.801% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 62.052% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 63.999% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 3396.961% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 578.988% |
| Biome Australia Limited | 7.66 Million AUD | 81.174% |
| Biotron Limited | -40.49 Thousand AUD | 3665.371% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 122.039% |
| BTC Health Limited | 16.36 Thousand AUD | -8725.819% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 80.628% |
| CSL Limited | 15.28 Billion AUD | 99.991% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 87.452% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 98.151% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 37.646% |
| Dimerix Limited | 583.47 Thousand AUD | -147.465% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 97.166% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -15.367% |
| Immuron Limited | 3.33 Million AUD | 56.728% |
| Imugene Limited | -5.83 Million AUD | 124.725% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -19.109% |
| Memphasys Limited | 1606.00 AUD | -89806.849% |
| Nanollose Limited | -348.95 Thousand AUD | 513.783% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.296% |
| Noxopharm Limited | -534.81 Thousand AUD | 369.984% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 1680.853% |
| Nyrada Inc. | -5164.07 AUD | 28060.581% |
| Orthocell Limited | 3.68 Million AUD | 60.853% |
| PharmAust Limited | -1641.00 AUD | 88089.275% |
| Patrys Limited | 1.39 Million AUD | -3.568% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -2441.548% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 228.554% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 61.106% |
| PYC Therapeutics Limited | 22.05 Million AUD | 93.454% |
| Race Oncology Limited | 1.38 Million AUD | -3.884% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 106.776% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 493.683% |
| Starpharma Holdings Limited | 7.65 Million AUD | 81.143% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.532% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -859.335% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -13940.296% |